Intellia Therapeutics (NTLA) Cash from Financing Activities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash from Financing Activities data on file, last reported at $33.6 million in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $33.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165.1 million (up 31.25% YoY) and the FY2025 annual result came in at $131.5 million, down 29.21% from the prior year.
• Cash from Financing Activities rose to $33.6 million in Q1 2026 per NTLA's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $505.8 million in Q4 2022 and bottomed at $2.0 million in Q4 2025.
• The 5-year median for Cash from Financing Activities is $28.8 million (2022), against an average of $66.5 million.
• The widest annual swing landed in 2022, when Cash from Financing Activities soared 22082.59%; it then plunged 97.82% in 2024.
• Tracing NTLA's Cash from Financing Activities over 5 years: stood at $505.8 million in 2022, then sank by 78.95% to $106.5 million in 2023, then sank by 97.82% to $2.3 million in 2024, then slipped by 14.67% to $2.0 million in 2025, then jumped by 1597.98% to $33.6 million in 2026.
• Per Business Quant, the three latest NTLA Cash from Financing Activities figures stand at $33.6 million (Q1 2026), $2.0 million (Q4 2025), and $114.9 million (Q3 2025).

Peer Comparison